The Library
An overview of models used in economic analyses of biologic therapies for arthritis-from current diversity to future consensus
Tools
Tools
Tools
Madan, Jason, Ades, A. E. and Welton, N. J. (2011) An overview of models used in economic analyses of biologic therapies for arthritis-from current diversity to future consensus. Rheumatology, 50 (Supplement 4). iv10- iv18. doi:10.1093/rheumatology/ker240
An open access version can be found in:
Official URL: https://doi.org/10.1093/rheumatology/ker240
Abstract
A number of cost-effectiveness models have been developed with the aim of providing guidance for decision making on biologic therapies for the management of inflammatory joint disease. The findings of these analyses can differ markedly, and these differences can undermine the credibility of such models if unexplained. To allow differences between models to be identified more easily, we define six components common to all models-initial response, longer term disease progression, mortality, quality-adjusted life year estimation, resource use and the selection and interpretation of data. We give examples of divergent approaches taken by model structures to the same issue, and explore the impact of divergence on model results, with particular focus on two models that have reported substantially different estimates for the cost-effectiveness of third-line etanercept vs conventional DMARD. The sensitivity of results to a particular assumption made in a model will depend on the decision problem and assumptions made elsewhere in the model, highlighting the importance of guidance throughout model development. To some extent, guidance from bodies such as the National Institute of Health and Clinical Excellence can be used to determine which approach should be preferred where models differ. However, there is a pressing need for clinical input and guidance before consensus can be reached on the most credible model(s) to use for decision support.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) | ||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
| Journal or Publication Title: | Rheumatology | ||||||
| Publisher: | Oxford University Press | ||||||
| ISSN: | 1462-0324 | ||||||
| Official Date: | September 2011 | ||||||
| Dates: |
|
||||||
| Volume: | 50 | ||||||
| Number: | Supplement 4 | ||||||
| Page Range: | iv10- iv18 | ||||||
| DOI: | 10.1093/rheumatology/ker240 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||
| Funder: | Arthritis Research UK | ||||||
| Open Access Version: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
